再発及び難治性急性骨髄性白血病に対するCytosine Arabinoside中等量療法

河野 文夫; 手島 安広; 田島 博之; 李 聖烈; 潮崎 明; 中井 良一; 帖佐 理子; 沢田 知宏; 前田 洋助; 溝国 民江; 有富 聡; 山川 慶多; 野村 裕常; 吉永 健; 麻生 範雄; 真田 功; 高月 清

doi:10.11406/rinketsu.27.315

The Use of Intermediate Dose Cytosine Arabinoside (ID Ara-C) in the Treatment in Relapsing or Refractory Cases of Acute Myelogeneous Leukemia

Fumio KAWANO, Yasuhiro TEJIMA, Hiroyuki TAJIMA, Sung-Yul LEE, Akira SHIOZAKI, Ryoichi NAKAI, Michiko CHYOSA, Tomohiro SAWADA, Yosuke MAEDA, Tamie MIZOKUNI, Satoru ARIDOMI, Keita YAMAKAWA, Hirotsune NOMURA, Takeshi YOSHINAGA, Norio ASO, Isao SANADA, Kiyoshi TAKATSUKI

Author information

Fumio KAWANO
The Second Department of Internal Medicine, Kumamoto University Medical School
Yasuhiro TEJIMA
The Second Department of Internal Medicine, Kumamoto University Medical School
Hiroyuki TAJIMA
The Second Department of Internal Medicine, Kumamoto University Medical School
Sung-Yul LEE
The Second Department of Internal Medicine, Kumamoto University Medical School
Akira SHIOZAKI
The Second Department of Internal Medicine, Kumamoto University Medical School
Ryoichi NAKAI
The Second Department of Internal Medicine, Kumamoto University Medical School
Michiko CHYOSA
The Second Department of Internal Medicine, Kumamoto University Medical School
Tomohiro SAWADA
The Second Department of Internal Medicine, Kumamoto University Medical School
Yosuke MAEDA
The Second Department of Internal Medicine, Kumamoto University Medical School
Tamie MIZOKUNI
The Second Department of Internal Medicine, Kumamoto University Medical School
Satoru ARIDOMI
The Second Department of Internal Medicine, Kumamoto University Medical School
Keita YAMAKAWA
The Second Department of Internal Medicine, Kumamoto University Medical School
Hirotsune NOMURA
The Second Department of Internal Medicine, Kumamoto University Medical School
Takeshi YOSHINAGA
The Second Department of Internal Medicine, Kumamoto University Medical School
Norio ASO
Division of Hematology, Laboratory Medicine, Kumamoto University Hospital
Isao SANADA
Blood Transfusion Service, Kumamoto University Medical School
Kiyoshi TAKATSUKI
The Second Department of Internal Medicine, Kumamoto University Medical School

Keywords: intermediate dose Ara-C, refractory leukemia

JOURNAL RESTRICTED ACCESS

1986 Volume 27 Issue 3 Pages 315-320

DOI https://doi.org/10.11406/rinketsu.27.315

Details

Abstract

Nine patients with acute myelocytic leukemia, 7 in relapse and 2 refractory to conventional therapy, were treated with intermediate dose cytosine arabinoside (ID Ara-C) in combination with doxorubicin and vincristine.
This schedule consists of 1h infusions of Ara-C in a dose of 500 mg/m² every 12h for 4 days (days 3∼6), in combination with doxorubicin 50 mg/m² on day 1 and vincristine 1 mg/m² on day 2.
In 9 evaluable courses, 5 courses (55.5%) achieved complete remission (CR).
Duration of the CR was 1.5, 2 and 2.6 months. respectively. Other two courses are still in CR (more than 1 and 7.2 months in duration).
Side effects were similar to those in the conventional treatment.
These preliminary data suggest that the therapeutic results of this ID Ara-C regimen are not inferior to comparable schedules with HD Ara-C as reported by others while toxicity is less severe.

Corresponding author

Register with J-STAGE for free!